The Axxent System, which delivers non-radioactive, electronic therapy directly to cancer sites with minimal radiation exposure to surrounding healthy tissue, is FDA-cleared for treatment of early stage breast cancer, endometrial cancer, skin cancer, and for the treatment of other cancers or conditions where radiation therapy is indicated, including IORT.

The Xoft eBx System uses a miniaturized X-ray source instead of a radioactive isotope to deliver radiation anywhere in the body.

Building on the growing utilisation of a multi-disciplinary approach for use of the eBx System to deliver IORT for breast and other cancers, Xoft also announced that more than 60 Axxent Systems have been installed across the country and thousands of patients have been treated with Electronic Brachytherapy.

Xoft president and CEO Michael Klein said multiple published studies have established the clinical benefits of isotope-free, 50 kV for the delivery of IORT. This has prompted an emerging shift in the marketplace, and many clinicians are realising the importance of IORT as part of their RT program.

“The Xoft system is optimally suited for IORT and it is not only engineered to be transportable and easy to bring to the OR, but can actually treat in just three easy steps,” Klein said.